ZIVO Bioscience (ZIVO) Stock Price, News & Analysis

Company Overview

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Key Stats

• Today's Range: $17.99 to $18.22
• 50-Day Range: $9.97 to $18.22
• 52-Week Range: $6.50 to $22.15
• Volume: 1,227 shs
• Average Volume: 1,041 shs
• Market Capitalization: $69.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZIVO Bioscience Stock Analysis - MarketRank™

ZIVO Bioscience scored higher than 5% of companies evaluated by MarketBeat, and ranked 927th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ZIVO Bioscience.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ZIVO Bioscience is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ZIVO Bioscience is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of ZIVO Bioscience has been sold short.

Short Interest Ratio / Days to Cover

ZIVO Bioscience has a short interest ratio ("days to cover") of 43.3, which indicates bearish sentiment.

Change versus previous month

Short interest in ZIVO Bioscience has recently decreased by 7.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ZIVO Bioscience does not currently pay a dividend.

Dividend Growth

ZIVO Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.64% of the float of ZIVO Bioscience has been sold short.

Short Interest Ratio / Days to Cover

ZIVO Bioscience has a short interest ratio ("days to cover") of 43.3, which indicates bearish sentiment.

Change versus previous month

Short interest in ZIVO Bioscience has recently decreased by 7.75%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added ZIVO Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ZIVO Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

48.90% of the stock of ZIVO Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.83% of the stock of ZIVO Bioscience is held by institutions.

ZIVO Stock Analysis - Frequently Asked Questions

How have ZIVO shares performed this year?

ZIVO Bioscience's stock was trading at $21.50 at the start of the year. Since then, ZIVO shares have decreased by 15.3% and is now trading at $18.22.

How were ZIVO Bioscience's earnings last quarter?

ZIVO Bioscience, Inc. (NASDAQ:ZIVO) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.06) EPS for the quarter. The biotechnology company earned $0.02 million during the quarter.

When did ZIVO Bioscience's stock split?

Shares of ZIVO Bioscience reverse split on Friday, October 27th 2023.The 1-6 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of ZIVO Bioscience?

Shares of ZIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ZIVO Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIVO Bioscience investors own include Canopy Growth (CGC), Meta Platforms (META), OPKO Health (OPK), Johnson & Johnson (JNJ), ACADIA Pharmaceuticals (ACAD), ARAVIVE (ARAV) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZIVO
• Previous Symbol: OTCMKTS:HEPI
• CIK: 1101026
• Web: www.zivobioscience.com
• Phone: (248) 452-9866
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.78 million
• Net Margins: N/A
• Pretax Margin: -17,113.75%
• Return on Equity: N/A
• Return on Assets: -2,240.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: $15.85 thousand
• Price / Sales: 4,387.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.81) per share
• Price / Book: -22.49

Miscellaneous

• Outstanding Shares: 3,817,000
• Free Float: 2,911,000
• Market Cap: $69.55 million
• Optionable: Not Optionable
• Beta: -0.06